Citi Downgrades GlaxoSmithKline (GSK) to Hold
Tweet Send to a FriendGet Alerts GSK Hot Sheet
Price: $52.97 +0.46%
Rating Summary:
3 Buy, 5 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 5 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade GSK Now!
Citi downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Hold.
For more ratings news on GlaxoSmithKline click here and for the rating history of GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $38.77 yesterday, with a 52 week range of $32.15-$42.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more ratings news on GlaxoSmithKline click here and for the rating history of GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $38.77 yesterday, with a 52 week range of $32.15-$42.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
- Ascendiant Capital Downgrades Buckle, Inc. (BKE) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
